Trials / Recruiting
RecruitingNCT07256015
Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy
"DEMOS" - Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to characterize the real-life experience of patients with moderate/severe psoriasis receiving deucravacitinib treatment, in terms of efficacy, safety, and health-related quality of life (HRQoL) in Italy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Deucravacitinib | According to the product label |
Timeline
- Start date
- 2025-08-05
- Primary completion
- 2027-07-05
- Completion
- 2027-08-05
- First posted
- 2025-12-01
- Last updated
- 2025-12-01
Locations
1 site across 1 country: Italy
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07256015. Inclusion in this directory is not an endorsement.